Investment Thesis
Pulse Biosciences exhibits severe fundamental weakness with $19.1M operating losses on only $401K revenue, indicating minimal commercial traction and unsustainable burn rate of $14.6M annually. While the $68.3M cash position and zero debt provide runway to continue operations for approximately 4-5 years, the company has yet to demonstrate a viable business model or path to profitability. Execution risk remains extremely high without evidence of significant revenue acceleration or operating leverage.
Strengths
- Strong balance sheet with $68.3M cash and zero long-term debt
- Exceptional liquidity position with 7.26x current ratio providing financial flexibility
- Minimal capital intensity with only $33K capex allows focus on product development and commercialization
Risks
- Catastrophic operating losses of $19.1M against $401K revenue indicates fundamental business model failure or extremely early stage with minimal market validation
- Negative operating cash flow of $14.6M annually will deplete cash runway within 4-5 years without achieving cash flow breakeven
- Extreme negative profitability metrics across all measures (-4775.6% operating margin, -4633.7% net margin) demonstrate complete lack of current business viability
Key Metrics to Watch
- Revenue growth rate and trajectory toward meaningful commercial scale from $401K baseline
- Operating cash burn rate trend and timeline to cash flow positive operations
- Gross margins and operating expense ratios once revenue begins scaling materially
- Cash runway depletion timeline and need for additional capital raises
- Path to operating breakeven and positive net income through either revenue growth or cost reduction
Financial Metrics
Revenue
401.0K
Net Income
-18.6M
EPS (Diluted)
$-1.50
Free Cash Flow
-14.6M
Total Assets
81.6M
Cash
68.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,775.6%
Net Margin
-4,633.7%
ROE
-28.0%
ROA
-22.8%
FCF Margin
-3,647.9%
Balance Sheet & Liquidity
Current Ratio
7.26x
Quick Ratio
7.24x
Debt/Equity
0.00x
Debt/Assets
18.8%
Interest Coverage
-30.35x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:59:15.525553 |
Data as of: 2026-03-31 |
Powered by Claude AI